Uzbekistan plans Biome center for cell technologies and genomics
Uzbekistan is moving ahead with a Biome center dedicated to cell technologies, genomics, and biobanking, aiming to strengthen its position in advanced bioscience research.
Uzbekistan is moving ahead with a Biome center dedicated to cell technologies, genomics, and biobanking, aiming to strengthen its position in advanced bioscience research.
Bristol Myers Squibb reports that its phase II QUINTESSENTIAL trial of arlocabtagene autoleucel met the main goal in adults with relapsed and refractory multiple myeloma.
Adam Nicolson became the first person in Scotland to receive CAR-T cell therapy for myeloma after exhausting all other options. Now in remission, his case is driving new research into the therapy’s potential for autoimmune diseases.